Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005. Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance treatment of bipolar disorder and examine how that evidence has been disseminated in the scientific literature. METHODS AND FINDINGS: We systematically searched multiple databases to identify double-blind, randomized controlled trials of aripiprazole for the maintenance treatment of bipolar disorder while excluding other types of studies, such as open-label, acute, and adjunctive studies. We then used a citation search to identify articles that cited these trials and rated the quality of their citations. Our evidence search protocol identified only two publications, both describing the results of a single trial conducted by Keck et al., which met criteria for inclusion in this review. We describe four issues that limit the interpretation of that trial as supporting the use of aripiprazole for bipolar maintenance: (1) insufficient duration to demonstrate maintenance efficacy; (2) limited generalizability due to its enriched sample; (3) possible conflation of iatrogenic adverse effects of abrupt medication discontinuation with beneficial effects of treatment; and (4) a low overall completion rate. Our citation search protocol yielded 80 publications that cited the Keck et al. trial in discussing the use of aripiprazole for bipolar maintenance. Of these, only 24 (30%) mentioned adverse events reported and four (5%) mentioned study limitations. CONCLUSIONS: A single trial by Keck et al. represents the entirety of the literature on the use of aripiprazole for the maintenance treatment of bipolar disorder. Although careful review identifies four critical limitations to the trial's interpretation and overall utility, the trial has been uncritically cited in the subsequent scientific literature. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“However, financial conflicts of interest have been found to be associated with biased reporting of outcomes in randomized trials [115,116], which serve as the evidence upon which treatment guideline recommendations are based.”
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“Traditionally, the clinical care of patients diagnosed with bipolar disorder has been divided into three phases (borrowed from clinical consensus about the phases of treatment for major depressive disorder [9,10]): treatment of acute episodes to symptomatic remission, continuation treatment to prevent relapse, and mai…”
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678 · cited 2×
“[83] was partly attributed to its enrollment of participants with low severity of illness [84]—and it was the last study to utilize the lithium-era prophylaxis design.”
Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.217 · Cited by 661
Conflict of Interest in the Debate over Calcium-Channel Antagonists
Stelfox, H. T., Chua, G., O'Rourke, K., & Detsky, A. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380206 · Cited by 615
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609 · cited 1×
“This limitation of the randomized discontinuation design has long been recognized by drug trialists [11,12,56,58–65] and is not dissimilar to criticisms voiced about the first generation of randomized trials evaluating the use of lithium for maintenance treatment in bipolar disorder, i.e., that…”
Coverage by the news media of the benefits and risks of medications
Moynihan, R., Bero, L., Ross-Degnan, D., Henry, D., Lee, K., Watkins, J., Mah, C., & Soumerai, S. B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422206 · Cited by 500 · cited 1×
“quality of news media reports of medication trials [37].”
Rising, K., Bacchetti, P., & Bero, L. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050217 · Cited by 328 · cited 1×
“reporting of outcomes in randomized trials [115,116], which serve”
Tohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., Baker, R. W., Chou, J. C.-Y., & Bowden, C. L. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.247 · Cited by 317 · cited 1×
“identify the low completion rate in the extension phase as a potential limitation but appeal to the low completion rates observed in other maintenance trials [47,48] to support the generalizability of their results.”
Keck, P. E., Calabrese, J. R., McQuade, R. D., Carson, W. H., Carlson, B. X., Rollin, L. M., Marcus, R. N., Sanchez, R., & Aripiprazole Study Group (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0414 · Cited by 290
Cited by
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Self-citationBerwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.047 · Cited by 101
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2016) · Focus · doi:10.1176/appi.focus.140202 · Cited by 20
“, not for relapse prevention or maintenance treatment [17,18]), placebocontrolled trials in which participants treated with antidepressant medications were randomly assigned to additionally receive an atypical antipsychotic medication or placebo.”
BackgroundResultSelf-citation
Metadata
- Authors
- Tsai, A. C., Rosenlicht, N. Z., Jureidini, J. N., Parry, P. I., Spielmans, G. I., & Healy, D.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-05-03
- Volume
- 8
- Issue
- 5
- Pages
- e1000434
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2146054111
- Cited by
- 43
- References
- 21
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature. https://app.cochat.ai/papers/10.1371/journal.pmed.1000434
- The paper
- Tsai, A. C., Rosenlicht, N. Z., Jureidini, J. N., Parry, P. I., Spielmans, G. I., & Healy, D. (2011). Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1000434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.